FilingReader Intelligence

Pharmaron invests $14m in private equity fund

March 27, 2025 at 08:15 PM UTCBy FilingReader AI

Pharmaron Beijing (SZSE:300759) announced its participation in a new private equity investment, committing 100 million yuan (approximately $14 million USD) to the "Ningbo Yongkang Equity Investment Partnership," pending regulatory approval. The investment aims to leverage specialized expertise and promote the high-quality development of the pharmaceutical sector in Ningbo, China. Pharmaron will act as a limited partner. Shanghai Hongfu Private Equity Fund Management Co., Ltd. will serve as the general partner and fund manager. The total fundraising target for the fund is 500 million yuan. The fund will primarily focus on investments in private equity and venture capital funds managed by third parties, targeting projects in the life science sector in the Ningbo area.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:300759Shenzhen Stock Exchange

News Alerts

Get instant email alerts when Pharmaron Beijing publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →